Bio-link Australia Pty. Ltd.

28th March 2017 – Oncology Venture – APO010 approved for testing in phase II multiple myeloma trial

Oncology Venture’s immuno-oncology drug APO010, a first-in-class FAS-ligand, will be tested in a subset of Multiple Myeloma patients identified as likely responders by the Drug Response Predictor (DRPTM) precision medicine technology. Read Full Story Here

oncology venture logo-1